Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study
Obesity · 2026
DOI: 10.1002/oby.70106 ↗At a glance
Randomisierte kontrollierte Studie in Obesity, 2026. Written by Harold E Bays and 9 co-authors. Institution: Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky, USA. Major MEDLINE topics: Obesity, Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Receptors, Gastrointestinal Hormone. Cited 14 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Viking Therapeutics, Inc..
Abstract (original language)
Objective
This study aimed to determine doses of VK2735, a novel glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide (GLP‐1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.
Methods
VENTURE was a phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study of weekly subcutaneous VK2735 in adults with obesity or overweight and ≥ 1 weight‐related comorbidity. Participants with diabetes mellitus were ineligible. The primary endpoint was percent change from baseline in body weight at Week 13. Secondary efficacy endpoints were observed and change from baseline weight loss and the proportion of participants losing ≥ 5% and ≥ 10% of baseline weight.
Results
Study was conducted between August 2023 and February 2024. Mean weight reduction with active treatment ranged from 9.2 kg (2.5 mg dose) to 14.6 kg (15 mg dose), corresponding to 9.1% and 14.7% weight reductions, respectively; the placebo group had a 1.8 kg (1.7%) reduction. In the active treatment groups, 93% (130/140) of participants had a ≥ 5% weight reduction, compared with 12% (4/34) of participants with placebo treatment. The common adverse events (AEs) were gastrointestinal, which decreased in reported frequency after dose titration to steady state.
Conclusions
All subcutaneous doses of VK2735 significantly reduced body weight. The AE profile of VK2735 was primarily gastrointestinal, with decreased reported frequency upon continued use. Trial Registration ClinicalTrials.gov identifier NCT06068946 image
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky, USA.
- Midwest Institute for Clinical Research, Indianapolis, Indiana, USA.
- Summit Clinical Research, San Antonio, Texas, USA.
- Mercury Street Medical, Butte, Montana, USA.
- Kansas City Research Institute, Kansas City, Missouri, USA.
- Orange County Research Center, Lake Forest, California, USA.
ORCID profiles: Harold E Bays
Funding
- Viking Therapeutics, Inc.
Cite
APA
Bays, H. E., Toth, P., Alkhouri, N., Pullman, J., Freilich, B., Neutel, J., Ji, S., Stubbe, S., Hedges, P., & Lian, B. (2026). Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study. Obesity. https://doi.org/10.1002/oby.70106
Vancouver
Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J, et al. Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study. Obesity. 2026. doi:10.1002/oby.70106
BibTeX
@article{Bays2026,
author = {Bays, Harold E and Toth, Phillip and Alkhouri, Naim and Pullman, John and Freilich, Bradley and Neutel, Joel and Ji, Summer and Stubbe, Scott and Hedges, Parke and Lian, Brian},
title = {Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70106}
}
EUVIMED